FOXO4-DRI (FOXO4-D-Retro-Inverso Peptide (Senolytic))
A D-retro-inverso peptide that disrupts FOXO4-p53 interaction in senescent cells, triggering selective apoptosis of senescent cells while sparing healthy cells.
How it works
Competitively disrupts FOXO4 sequestration of p53 in senescent cells, releasing p53 to trigger intrinsic apoptosis selectively in cells relying on this survival mechanism.
Key facts
- Molecular weight: ~4,500 Da
- Half-life: 12-24 hours (D-amino acid stability)
- Bioavailability: Moderate (SubQ)
- Storage: Lyophilized: -20°C. Light-sensitive.
Dosing overview
- Typical dose: 5-10 mg/kg (animal studies)
- Frequency: 3x per week for 3 weeks
- Duration: 3-week cycles
- Route: Subcutaneous
Reported benefits
- Selective senescent cell elimination
- Potential aging reversal
- Improved tissue function
- Reduced inflammatory burden
- Hair regrowth (mice)
Possible side effects
- Limited human safety data
- Transient inflammatory response possible
- Theoretical beneficial-senescence depletion
Research
- Targeted apoptosis of senescent cells restores tissue homeostasis (2017): Selectively induced apoptosis in senescent cells, restored fitness, fur density, and renal function in aged mice.
- FOXO4-p53 disruption as senolytic strategy (2021): Cleared 60% of senescent cells in aged livers with reduced SASP inflammatory markers.
Compare FOXO4-DRI
Community discussions about FOXO4-DRI
- Thoughts on the senolytic potential of FOXO4-DRI - 4 comments
- Thoughts on the Immortality Stack and senolytics - 0 comments
- Combining NMN with the Immortality Stack? - 6 comments
- FOXO4-DRI flu-like symptoms – has anyone else felt this? - 7 comments
- Feedback on my 4‑week Immortality Stack run – doses and timing - 6 comments
- Ask the community about FOXO4-DRI
Research and educational reference only. Not medical advice.